COMPANY

Trophogen Inc.

HQ: Rockville, MD source · trophogen.com ↗ · Mid-Atlantic

Keywords: From press sources:oncology thyroid cancer

Location: Rockville, MD · source · Oct 15, 2026

Profile checked Oct 10, 2026

28NIH grants

NIH awards 28

Annual award amounts. Total $16.0M.

Jul 23, 2021 NIH award 5R44CA224376-04 FY2021: $345,085 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel Long Acting rhTSH Superagonist Analo source ↗
Sep 21, 2020 NIH award 5R44CA224376-03 FY2020: $433,685 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel Long Acting rhTSH Superagonist Analo source ↗
Apr 2, 2020 NIH award 5R44HD094408-03 FY2020: $727,601 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel Recombinant High-Affinity, Long- and source ↗
Sep 4, 2019 NIH award 4R44CA224376-02 FY2019: $778,770 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel Long Acting rhTSH Superagonist Analo source ↗
Apr 16, 2019 NIH award 5R44HD090804-03 FY2019: $942,701 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Novel and Affordable Neogly source ↗
Mar 21, 2019 NIH award 2R44HD094408-02 FY2019: $733,166 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel Recombinant High-Affinity, Long- and source ↗
Aug 1, 2018 NIH award 1R44CA224376-01A1 FY2018: $285,070 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel Long Acting rhTSH Superagonist Ana source ↗
Mar 1, 2018 NIH award 4R44HD090804-02 FY2018: $825,420 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Novel and Affordable Neogly source ↗
Sep 18, 2017 NIH award 1R43HD094408-01 FY2017: $138,880 awarded for that fiscal year; activity R43 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel Recombinant High-Affinity, Long- and source ↗
Aug 18, 2017 NIH award 1R44HD090804-01A1 FY2017: $299,999 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Novel and Affordable Neog source ↗
Jun 4, 2015 NIH award 5R44CA171352-03 FY2015: $765,782 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel High Affinity VEGF Analogs For Targe source ↗
Apr 21, 2014 NIH award 4R44CA171352-02 FY2014: $825,054 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel High Affinity VEGF Analogs For Targe source ↗
Jul 8, 2013 NIH award 5R44HD060321-06 FY2013: $972,062 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superactive Analogs of FSH source ↗
May 10, 2013 NIH award 1R44CA171352-01A1 FY2013: $283,958 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel High Affinity VEGF Analogs For Tar source ↗
Sep 12, 2012 NIH award 1R43FD004417-01 FY2012: $150,000 awarded for that fiscal year; activity R43 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Novel High Affinity and Long-Acting Bovine source ↗
Jul 13, 2012 NIH award 5R44HD060321-05 FY2012: $972,062 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superactive Analogs of FSH source ↗
Sep 13, 2011 NIH award 2R44HD060321-04A2 FY2011: $972,062 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superactive Analogs of FS source ↗
Sep 1, 2011 NIH award 5R44DK076302-04 FY2011: $910,851 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Recombinant Human TSH Superagonists for Im source ↗
Jul 23, 2010 NIH award 2R44DK076302-03 FY2010: $829,058 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Recombinant Human TSH Superagonists for Im source ↗
Jul 30, 2009 NIH award 5R44DK075174-03 FY2009: $880,167 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superagonist Analogs of Rec source ↗
Aug 11, 2008 NIH award 2R44DK075174-02 FY2008: $894,568 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superagonist Analogs of Rec source ↗
Aug 22, 2007 NIH award 5R43DK076302-02 FY2007: $239,423 awarded for that fiscal year; activity R43 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Recombinant Human TSH Superagonists for Im source ↗
Mar 1, 2007 NIH award 5R44DK064521-03 FY2007: $616,035 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superactive Analogs of Foll source ↗
Sep 21, 2006 NIH award 1R43DK076302-01 FY2006: $239,423 awarded for that fiscal year; activity R43 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Recombinant Human TSH Superagonists for Im source ↗
Jun 12, 2006 NIH award 1R43DK075174-01 FY2006: $101,500 awarded for that fiscal year; activity R43 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superagonist Analogs of Rec source ↗
Mar 3, 2006 NIH award 2R44DK064521-02A1 FY2006: $601,233 awarded for that fiscal year; activity R44 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superactive Analogs of FS source ↗
Sep 2, 2005 NIH award 1R43DK072632-01 FY2005: $108,000 awarded for that fiscal year; activity R43 (SBIR); PI SZKUDLINSKI, MARIUSZ W; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Novel VEGF Analogs source ↗
Jun 4, 2004 NIH award 1R43DK064521-01 FY2004: $100,000 awarded for that fiscal year; activity R43 (SBIR); PI WEINTRAUB, BRUCE DALE; recipient as written: TROPHOGEN, INC., ROCKVILLE, MD. Development of Superactive Analogs of LH a source ↗